**Minutes ORF Meeting Marseille, 28th March 2017**

**Present** Anna Sureda (AS), Hervé Finel, Ariane Boumendil, , Peter Dreger (PD), Silvia Montoto (SM), Stephen Robinson (SR), Chara Kyriakou (CK), Saad Akhtar, Irma Khvedelidze, Alina Tanase, Leyre Bento (LB), Irfan Maghfoor, Marleen van Os, Jennifer Clay, Ali Bazarbachi (AB), Lajos Gergely, Kai Hübel, Jordan Gauthier, Sonja Genadieva-Stavrik, Harry Schouten, Ivetta Danylesko, Christian Gisselbrecht, Sandy Amorim, Zsuzsanna Leitnerné Kósa, Karan Wadehra (KW), Alberto Mussetti, Maria Speranza Massei, Osman Ilhan, Zafer Gülbas, Alessandro Re, Raquel Del Campo, Joanna Romejko-Jarosinska, Milan Navratil, Rosanna Ghinai, Charlotte Chaibi, Olivier Hermine, Jean El-Cheikh

**General Matters**

**1. CIBMTR Collaboration (Peter Dreger)**

**Discussions were held between members of the CIBMTR Lymphoma Working Committee and PD and AS at the last Tandem Meetings. There was agreement to develop the following projects:**

1. **Consensus projects on conditioning regimens for alloSCT in lymphoma (to be led by the EBMT LWP –PD-)**
2. **Consensus projects on post transplant maintenance strategies**

**2. Timelines for abstracts preparation (Silvia Montoto): Proposal for new internal timeline for abstract submission to enable timely review of the abstract by PI, writing committee, statistician and then co-authors. The following timeline was proposed and accepted:**

**-day 0: deadline for submission
-day -2: final abstract approved by PIs and LWP chair
-day -10: abstract to be sent to co-authors
-day -15: PI to send first draft to Writing Committee
-day -30: Ariane to send the first analysis**

**Externally for other WP: SM will send a proposal to Nicolaus Kroeger asking to discuss this at the SC and establish common timelines for all WPs.**

**Educational Matters**

**The 13th Educational Course will be held in Prague 21st and 22nd September 2017**

**Bids for 2018: Palma de Mallorca (host LB) and Bristol (host SR) were both proposed. It was agreed that Palma de Mallorca should be taken forward.**

**A new application form for centers wishing to host the Educational Course has been developed (see Appendix). Future bids should include potential venue and hotels to be considered.**

**Manuscript Status**

 **2006-R-02 RIC in MCL; SR, 1st draft written**

 **2007-R-01 HL auto late effects update; AS/PD, 1st draft written**

 **2009-R-06 FL unrelated; AS, with CIBMTR, submitted to JCO**

 **2010-N-02 WM auto; CK, 1st draft written**

 **2011-R-01 PMBCL auto; IA, submitted to BMT**

 **2012-R-04 MALT; AC/SM, 1st draft written**

 **2012-R02E CTCL recent era; RD/ED, 1st draft written**

 **2013-R-03 Z-BEAM; LB/SM, accepted in BMT**

 **2015-R-02 IVL PEL; JM/PD, accepted in BMT**

 **2013-R-04 Haplo HL; CM/AS, submitted to JCO, response to referees pt**

 **2015-R-05 Allo in NHL according to age; CK/PD, TBW**

 **2015-R-01H BV as bridge to SCT in HL; AS/AB, 1st draft written**

 **2015-R-04 HIV new era; KH, TBW**

 **2015-R-06 SCT in NLP-HL; SA/AS, 1st draft written**

 **1998-P-01 Lym1-long follow up; RP/SM, TBW**

 **2016-R-05 BEAC toxicity; SR/SM, TBW**

**Ongoing LWP Studies**

**2009-N-02 SCT in blastic plasmacytoid dendritic cell neoplasia (SD with ALWP)**

**2013-N-02, 2016-R-01 PWI pre and post allo studies (PD, with CMWP) More data available on PWI pre allosct than post**

**2014-R-01 alloWM (CK)**

**2015-R-03 Rel after auto DLBCL (AS)**

**2015-R-01A BV as bridge to SCT in ALCL (AS/ED)**

**2015-R-09 FL Rel post auto in FL (SR)**

**2015-R-08 Haplo in DLBCL (PD/AS with CIBMTR) 49 haplo with PTC**

**2016-S-01 Checkpoint inhibitors pre/post alloHCT (SD/PD/AS).**

**To concentrate on CPI post allo.**

**Abstracts for 2017**

**Abstracts accepted for EBMT:**

* **Auto in HIV- oral (KH)(paper for JCO)**
* **Ibrutinib pre allo in CLL and MCL- oral (PD with CMWP)**
* **Ibrutinib post allo (with CMWP)**
* **auto BV in ALCL- poster (EDomingo)**
* **BV pre in HL- oral (AB)**
* **RICallo in MCL- oral (SR) (paper for Annals Oncol)**
* **BEAC toxicity- oral SR (paper for BMT)**

**Abstracts submitted to ICML** **Lugano 2017**

* **BV post allo in HL (AB)**
* **Allo BV in ALCL (AS, EDomingo)**
* **Lym1 (RPettengell)**

**Abstracts for ASH 2017:**

* **Rel post auto DLBCL (AS)**
* **WM consensus (CK, SM)**
* **CI pre/post allo (PD, SD)**
* **Rel post auto FL (SR)**

**New studies to be launched**

* 2016-R-02 DLI in lymphoma, (SR) Details of required data fields to be established
* 2016-R-04 2nd auto in HL, (CM/AS)
* [2016-R-03 Trends in SCT in HL, (AS)] pending formal proposal

**New Proposals**

**1. Trends in SCT in FL- KW and SR**

Observational study of transplant activity in FL over last 2-3 decades with outcome analysis and possible reference to population survival curves. Only Med A level data required. This study was supported to go ahead.

**2. Haploidentical SCT in Lymphoma. Identification of pretransplant factors impacting on outcome of transplant (AB)**

The preliminary proposal was discussed. Agreement on the importance of the study so it was supported. Recommended that the proposal required further refinement and then a feasibility analysis before it could be taken any further.

**Next Meeting of the ORF**: 20th September 2017 Prague

Appendix

|  |
| --- |
| EBMT EDUCATION & EVENTS UNIT |
| 2017 EVENT PROPOSAL FORM |
| GENERAL INFORAMTION |  |  |  |  |  |
| Title of the proposed meeting: |   |
| Organizing Working Party(s):Please state if there will be more than one WP will be involved |   |
| Proposed dates for the meeting:Please indicate start /end date | TBD with LWP |
| Organizing & Scientific Committee:Please name all members of the committee (e.g. WP Chair, Secretary etc) |   |
| LOGISTICS |   |   |   |   |   |
| **Proposed City / Country:** |  |
| **Possible Venues:Please list 3 possible venues that would be suitable for this event (in case venue(s) is not an hotel please suggest the nearby hotels for the invited speakers / chairs)** |  |
| **Possible Hotel(s) for Accommodation:** |  |
| Expected Number of Attendees: |   |
| Expected Number of Speakers / Chairs: |   |
| Proposed Registration Fee: |   |
| Travel Allowance:Please note that all the invited speakers / chairs should arrange their own travel. As a WP you can allow your invited speakers / chairs to reimburse their expenses.Please indicate the maximum amount you would like to allow per person. (please see the comment on the box) | 400€ for European Flights750€ for Middle East Flights1500€ for Overseas Flights |
| SPONSORSHIP |   |   |   |   |   |
| Possible Sponsors:Please list all possible sponsors for the meeting |   |
| SCIENTIFIC |   |   |   |   |   |
| Will meeting have Lunch Symposium(s)?: |   |
| Will there be Paralel Sessions?: |   |
| Will there be Workshops?: |   |
| Will the meeting be accredited by CME?: |   |
| Other:Please specify |   |
| SOCIAL |   |   |   |   |   |
| Will there be a Social Event:such as Dinners, Cocktail, Meet the Experts Thematic dinners etc. |   |
| Is there any other requirements?:Such special technical support, Web Cast etc. |   |
| Name / Surname: |   |
| Name / Surname:In case more than one WP |   |
| Name / Surname:In case more than one WP |   |
| Date of Submission: |   |
| Signature(s): |   |